Assessment of Hematological Biomarkers, Including Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios, in Diabetic Nephropathy for Patients with Type 2 Diabetes
/ 0
- Details
- Category: Vol. 92, June 2024
- Hits: 85
Assessment of Hematological Biomarkers, Including Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios, in Diabetic Nephropathy for Patients with Type 2 Diabetes, AHMED FATHY MOHAMED, MAHMOUD NASSAR, RANA Sh.M. MAHER, OLFAT SHAKER and YASMINE ABDELFATAH MOHAMED
Background: Diabetic nephropathy (DN) is a significant T2DM complication. The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are tested for their ability to detect DN in T2DM patients. Aim of Study: To evaluate the role of inflammatory mark-ers (neutrophil to lymphocyte ratio and platelet to lymphocyte ratio) in the detection of early diabetic nephropathy in Egyp-tian patients. Patients and Methods: A cross-sectional study was con-ducted on 150 patients with T2DM. The albumin-to-creatinine ratio divided participants into normoalbuminuria, microalbu-minuria, and macroalbuminuria. Complete blood counts were used to calculate NLR and PLR and analyze their relationship to DN stages. Results: This study revealed insightful findings about the relationships among various hematological biomarkers and DN in patients with T2DM. Notably, while the NLR and PLR did not directly correlate with DN, a significant positive correlation was discovered between NLR and total leukocyte count (TLC), shedding light on the intricate link between leukocyte dynamics and diabetes. Additionally, the study found encouraging results in terms of glycemic control; pa-tients with well-managed diabetes exhibited lower levels of both NLR and PLR. Moreover, an increased monocyte-to-lymphocyte ratio (MLR) was associated with poor glycemic control, highlighting its potential as a marker for monitoring diabetes management. Conclusion: This study does not directly link NLR and PLR to DN, but it opens new avenues for using these ratios as part of a broader diagnostic framework for DN risk in patients with T2DM. The study emphasizes the complexity of DN pathogenesis and the importance of systemic inflammation, supporting the idea that a multi-biomarker approach could im-prove DN risk assessment. This knowledge of T2DM and DN hematological biomarker dynamics helps improve patient out-comes through early detection and tailored management.